BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27754445)

  • 1. L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.
    Mohamed SA; Elshal MF; Kumosani TA; Aldahlawi AM; Basbrain TA; Alshehri FA; Choudhry H
    Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27754445
    [No Abstract]   [Full Text] [Related]  

  • 2. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
    Walenciak J; Wyka K; Janczar S; Młynarski W; Zalewska-Szewczyk B
    Pharmacol Rep; 2019 Apr; 71(2):311-318. PubMed ID: 30826572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
    Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
    Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
    BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
    Mehta RK; Verma S; Pati R; Sengupta M; Khatua B; Jena RK; Sethy S; Kar SK; Mandal C; Roehm KH; Sonawane A
    J Biol Chem; 2014 Feb; 289(6):3555-70. PubMed ID: 24297177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin potentiates antitumor activity of L-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia.
    Wang H; Geng QR; Wang L; Lu Y
    Leuk Lymphoma; 2012 Jul; 53(7):1376-82. PubMed ID: 22185211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
    Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
    Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of anti L-asparaginase antibody in childhood acute lymphoblastic leukemia].
    Akazai A; Oda M; Nishiuchi R; Horiuchi T; Henmi M; Manki A; Seino Y
    Rinsho Ketsueki; 1996 Feb; 37(2):95-100. PubMed ID: 8852025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
    Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEG-asparaginase.
    Fu CH; Sakamoto KM
    Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.
    Ghasemi A; Asad S; Kabiri M; Dabirmanesh B
    Appl Microbiol Biotechnol; 2017 Oct; 101(19):7227-7238. PubMed ID: 28801829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Sandlund JT; Ribeiro RC; Rivera GK; Rubnitz JE; Harrison PL; Wang B; Evans WE; Pui CH; Relling MV
    J Clin Oncol; 2000 Apr; 18(7):1525-32. PubMed ID: 10735901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
    Burke MJ; Zalewska-Szewczyk B
    Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
    Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between Gallic acid and Asparaginase to potentiate anti-proliferative effect on lymphoblastic leukemia cell line.
    Sourani Z; Shirzad H; Shirzad M; Pourgheysari B
    Biomed Pharmacother; 2017 Dec; 96():1045-1054. PubMed ID: 29217160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
    Avramis VI; Panosyan EH
    Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
    Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
    Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the anti-leukemia effect and mechanism of L-asparaginase between two different strains].
    Wang KM; Xu HG; Guo HX; Jin SW; Luo XQ; Fang JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):692-7. PubMed ID: 24989278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Update on L-asparaginase treatment in paediatrics].
    Moscardó Guilleme C; Fernández Delgado R; Sevilla Navarro J; Astigarraga Aguirre I; Rives Solà S; Sánchez de Toledo Codina J; Fuster Soler JL; Parra Ramirez L; Molina Garicaño J; González Martínez B; Madero López L
    An Pediatr (Barc); 2013 Nov; 79(5):329.e1-329.e11. PubMed ID: 23727426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.